FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Respons	ses)															
1. Name and Address ORBIMED ADVIS	2. Issuer Name an PIERIS PHARM]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner									
601 LEXINGTON	3. Date of Earliest 7 02/13/2018	ransaction	(Mon	nth/Day/Y	ear)			filed by One Reporting Person								
NEW YORK, NY	4. If Amendment, D	ate Origina	ıl File	cd(Month/Da	ay/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X_ Form filed by More than One Reporting Person									
(City)	(State)	(Zip)	Ta	able I - Nor	ı-Der	rivative S	ecuritie	s Acqu	ired, Disposed of	, or Beneficially C	(Check all applicable) _X					
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transact Code (Instr. 8)	tion	4. Secur (A) or D (Instr. 3,	isposed 4 and 5 (A) or	of (D)	5. Amount of Sec Beneficially Owr Reported Transac (Instr. 3 and 4)	ned Following	Ownership Form: Direct (D) or Indirect (I)	of Indirect Beneficial Ownership				
Common Stock		02/13/2018		M	<u> </u>		A	\$ 4.68	5,506,787		I	Footnotes				
Common Stock		02/13/2018		М		58	A	\$ 4.68	49,328		I	Footnotes				
Common Stock		02/13/2018		М		1,765	A	\$ 5.08	5,508,552		I	Footnotes				
Common Stock		02/13/2018		M		17	A	\$ 5.08	49,345		I	Footnotes				
Common Stock		02/13/2018		S		7,822	D	\$ 8.98	5,500,730		I	Footnotes				
Common Stock		02/13/2018		S		75	D	\$ 8.98	49,270		I	Footnotes				
Reminder: Report on a	ı separate line for ε	each class of securities	es beneficially owne	-	Personta	ons who	this fo	rm are	the collection o e not required to valid OMB cont	respond unles		1474 (9-02)				
			Derivative Securiti e.g., puts, calls, wa						ly Owned							
1. Title of 2.	3. Transaction	3A. Deemed		umber 6. E				7. Titl	e and 8. I	Price of 9. Number	of 10.	11. Natu				

Security	Conversion	Date (Month/Day/Year)	Execution Date, if	Code	ion	of Der Seco Acq (A) Disp of (I	osed D) r. 3, 4,		Amount of Underlying		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$ 4.68	02/13/2018		M			6,057	(1)	02/15/2018	Common Stock	6,057	\$ 0	0		See Footnotes (3) (5) (6)
Stock Option (right to buy)	\$ 4.68	02/13/2018		M			58	(1)	02/15/2018	Common Stock	58	\$ 0	0	I	See Footnotes (4) (5) (6)
Stock Option (right to buy)	\$ 5.08	02/13/2018		M			1,765	(2)	02/15/2018	Common Stock	1,765	\$ 0	0	I	See Footnotes (3) (5) (6)

Stock Option (right to	\$ 5.08	02/13/2018	M		17	<u>(2)</u>	02/15/2018	Common Stock	17	\$ 0	0	See Footnotes (4) (5) (6)
buv)												

Reporting Owners

P. C. N. /All	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
ORBIMED ADVISORS LLC 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK, NY 10022		X					
OrbiMed Capital GP III LLC 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK, NY 10022		X					

Signatures

/s/ Sven H. Borho, Member of OrbiMed Advisors LLC	02/15/2018
**Signature of Reporting Person	Date
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC	02/15/2018
-*Signature of Reporting Person	Date
/s/ Jonathan T. Silverstein, Member of OrbiMed Advisors LLC	02/15/2018
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The stock options were included in an award to Chau Khuong, an employee of the Reporting Persons, made on October 25, 2017 for services as a director of the Issuer. The award (1) included stock options relating to a total of 6,115 shares of the Issuer's Common Stock and was vested and exercisable on October 25, 2017. Mr. Khuong is no longer a director of the Issuer
- The stock options were included in an award to Chau Khuong, an employee of the Reporting Persons, made on January 25, 2018 for services as a director of the Issuer. The award (2) included stock options relating to a total of 1,782 shares of the Issuer's Common Stock and was vested and exercisable on January 25, 2018. Mr. Khuong is no longer a director of the Issuer.
 - These Shares are held of record by OrbiMed Private Investments III, LP ("OPI III"). OrbiMed Capital GP III LLC ("GP III") is the general partner of OPI III, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP III. By virtue of such relationships, GP III.
- (3) and Advisors may be deemed to have voting and investment power over the securities held by OPI III and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI III.
- These Shares are held of record by OrbiMed Associates III, LP ("Associates III"). Advisors is the general partner of Associates III. By virtue of such relationships, Advisors may be deemed to have voting and investment power over the securities held by Associates III and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by Associates III.
- (5) Samuel D. Isaly, who was included as a Reporting Person on previous reports under Section 16 of the Exchange Act filed by GP III and Advisors, is no longer subject to Section 16 with respect to securities of the Issuer.
- This report on Form 4 is jointly filed by GP III and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule (6) 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.